logo-loader
HealthPharma & Biotech
viewAllergy Therapeutics PLC

Allergy Therapeutics tipped to rise to 32p in coming months

Allergy Therapeutics plc (LON:AGY) shares may rise to around 32p in the next three to six months, so says Tip TV presenter and technical analyst Zak Mir.

The chartists call is deemed good whilst Allergy share hold above 21.9p per share.

Quick facts: Allergy Therapeutics PLC

Price: 11.75 GBX

AIM:AGY
Market: AIM
Market Cap: £74.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read